Skyrizi market forecast improves on rising global demand

The Business Research Company says the global Skyrizi market is set for stronger growth through 2035 as autoimmune diagnoses rise, biologic use expands and demand increases across dermatology and gastroenterology. North America held the largest share in 2025, while IL-23-targeted therapies and longer dosing intervals are emerging as key market trends.

Why it matters: - Skyrizi is part of a fast-growing biologics market tied to autoimmune disease treatment. - Rising demand could widen use across psoriasis, psoriatic arthritis, Crohn’s disease and other inflammatory conditions. - The forecast points to continued investment in targeted therapies and more convenient treatment options.

What happened: - The Business Research Company released its Global Market Report 2026 on the Skyrizi market. - The report covers market size, trends and forecasts for 2026-2035. - The report says North America held the largest share of the Skyrizi market in 2025. - The report projects North America will be the fastest-growing region during the forecast period.

The details: - Skyrizi is a prescription medication used to treat moderate to severe plaque psoriasis, active psoriatic arthritis and Crohn’s disease. - Skyrizi works by targeting and inhibiting interleukin-23, or IL-23, to reduce inflammation. - The report links market growth to higher autoimmune disease diagnoses and the limits of traditional immunosuppressive therapies. - It also points to broader use of biologics in dermatology and gastroenterology, wider access to specialty care and higher clinical trial success rates. - Forecast growth is expected to be supported by expansion into new inflammatory indications and more investment in next-generation biologics. - Other drivers include patient demand for more convenient dosing schedules, a focus on durable remission and updated biologic treatment guidelines. - The report identifies several emerging trends, including IL-23-targeted therapies, broader use across autoimmune diseases, longer dosing intervals, self-administered injectable formats and a greater emphasis on long-term disease management. - The report says personalized medicine is a major growth driver because treatment is increasingly tailored to genetics, environment and lifestyle. - The report says Skyrizi fits that approach because its targeted mechanism can improve efficacy and reduce side effects. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 reports also include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis. - Download a free sample of the report. - View the full report.

Between the lines: - The market thesis depends less on one drug alone and more on the broader shift toward targeted biologics. - Longer dosing intervals and self-injection features matter because convenience can influence patient adherence and provider adoption. - The emphasis on personalized medicine suggests future competition will likely center on precision, safety and durability, not just efficacy.

What's next: - The market is expected to grow through 2035 as new indications and biologic innovations expand the treatment pool. - Companies and providers are likely to focus on therapies that combine targeted action with easier dosing and longer-term disease control. - Regional demand patterns will remain important as North America leads now, but other global markets continue to open up.